Navigation Links
Southern Research Scientists to Present New Data at the American Association for Cancer Research 102nd Annual Meeting in Orlando
Date:3/29/2011

BIRMINGHAM., Ala., March 29, 2011 /PRNewswire-USNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and drug development today announced that its scientists will be delivering 13 poster presentations at the AACR 102nd Annual Meeting 2011, April 2-6, in Orlando, Fla. Southern Research will also be available to meet with scientists at Booth #543.

Southern Research has discovered more than 20 anti-cancer drugs which have been accepted into clinical trials. Of those, seven have received FDA approval, with six additional drugs currently in late stage preclinical and early clinical trials. Further, Southern Research has evaluated 50 percent of all other FDA-approved cancer drugs on the market. Contract research services include basic research and target identification, lead discovery and optimization, preclinical development and clinical trials support.

Southern Research scientists will present new preclinical data posters in the Exhibit Hall:

Sunday April 3, 2011

1:00 p.m. – 5:00 p.m.

#837:  Novel sulindac derivatives that inhibit colon cancer growth by a cyclooxygenase-independent mechanism involving PDE5 inhibition and the suppression of nuclear Beta-catenin levels   (Exhibit Hall A4-C, Poster Section 34)

Monday April 4, 2011

8:00 a.m. – 12:00 p.m.

#1053:  Mouse Kremen 1 negatively regulates Wnt/Beta-catenin signaling in human breast cancer MDA-MB-231 cells   (Exhibit Hall A4-C, Poster Section 3)

#1853: PDE5 suppression selectively induces apoptosis of human breast tumor cells and attenuates Wnt/Beta-catenin mediated transcription   (Exhibit Hall A4-C, Poster Section 34)

#1865:  Colon cancer chemopreventive properties of a non-cyclooxygenase inhibitory amide derivative of sulindac   (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#2537:  Novel 2'-deoxycytidine analogs as DNA demethylation agents (Exhibit Hall A4-C, Poster Section 26)

Tuesday April 5, 2011

8:00 a.m. – 12:00 p.m.

#3114:  Effects of tumor-stromal interactions on gene expression in panel of mouse tumor models   (Exhibit Hall A4-C, Poster Section 11)

#3707:  Sulindac sulfide inhibits growth and induces apoptosis of human colon tumor cells by a cGMP-dependent pathway leading to suppression of Beta-catenin transcription activity (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#4418:  Affymetrix whole genome microarray analysis of 24 human tumor xenograft models and the cell lines from which they were developed: Clustering of targets vs tumor tissue of origin   (Exhibit Hall A4-C, Poster Section 24)

#4265: Bithionol as an inhibitor of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

#3943:  Affymetrix whole genome microarray analysis of 51 human tumor cell lines representative of 16 different tissues of origin: Unsupervised hierarchical clustering

(Exhibit Hall A4-C, Poster Section 6)

#4610:  NO-NSAIDs inhibit colon tumor cell growth by a cGMP-independent mechanism (Exhibit Hall A4-C, Poster Section 33)

Wednesday April 6, 2011

8:00 a.m. – 12:00 p.m.

#5443:  A novel biosensor for monitoring intracellular cGMP in live cells (Exhibit Hall A4-C, Poster Section 29)

#5154: Serotonin signaling as a novel target of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

Southern Research will also have members of its new preclinical, non-invasive imaging team at Booth #543 on hand to discuss this new service.

ABOUT SOUTHERN RESEARCH

Southern Research Institute, founded in 1941, is an independent non-profit organization conducting basic and applied research and development.  More than 530 employees support commercial and government clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy sectors through technology out-licensing, sponsored research, and strategic collaborations.  Headquartered in Birmingham, Ala., Southern Research has facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., Washington, DC and Kiev, Ukraine. For more information about our capabilities, contact us by email at BusDev@SouthernResearch.org or call 888-322-1166 (U.S.) or 1-205-581-2830 (International.)

Contact: Rhonda Jung
205-337-9634
Jung@SouthernResearch.org


'/>"/>
SOURCE Southern Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Southern Home Medical Equipment Appoints Jerry Overcash to the Board of Directors
2. Southern Home Medical Equipment Engages Northern Virginia Based Waterford Holdings Group to Evaluate and Consider Acquisition Candidates in the Mid-Atlantic Area
3. Encinitas Nursing and Rehabilitation Center First in Southern California to Deploy Voice Technology for Outcomes-Based Care
4. MinuteClinic and St. Rose Dominican Hospitals Form Clinical Collaboration to Improve Access to Health Care in Southern Nevada
5. BioSpace Showcases Southern Californias Growing Life Science Region
6. Southern Research Announces Completion of $20 Million Bond Transaction
7. Southern California Cell Company Partners With Northern California Life Science Research Technology Company for Developing Human Derived Disease Specific iPS Cell Lines
8. Pro Medicus/Visage Imaging Signs Deal with Sydney-based Southern Radiology
9. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
10. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
11. Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):